GenSight Biologics announces a pooled presentation of LUMEVOQ versus natural history in ND4-LHON.
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced the publication of updated efficacy results from a pooled analysis of… Read More »GenSight Biologics announces a pooled presentation of LUMEVOQ versus natural history in ND4-LHON.